T-cell co-stimulatory blockade in transplantation: two steps forward one step back!

Bibliography

• Sayegh MH, Carpenter CB. Transplantation 50 years later–progress, challenges, and promises. N Engl J Med 2004;351(26):2761-6
   PubMed Web of Science ®Google Scholar
• Kahan BD. Cyclosporine. N Engl J Med 1989;321(25):1725-38
   PubMed Web of Science ®Google Scholar
• Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349(10):931-40
   PubMed Web of Science ®Google Scholar
• Myers BD, Newton L. Cyclosporine-induced chronic nephropathy: an obliterative microvascular renal injury. J Am Soc Nephrol 1991;2(2 Suppl 1):S45-52
   Google Scholar
• Pillebout E, Nochy D, Hill G, et al. Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant 2005;5(5):1120-9
   PubMed Web of Science ®Google Scholar
• Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009;87(2):233-42
   PubMed Web of Science ®Google Scholar
• Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998;338(25):1813-21
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013;13(4):227-42
   PubMed Web of Science ®Google Scholar
• Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996;14:233-58
   PubMed Web of Science ®Google Scholar
• Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990;248(4961):1349-56
   PubMed Web of Science ®Google Scholar
• Fraser JD, Irving BA, Crabtree GR, Weiss A. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 1991;251(4991):313-16
   PubMed Web of Science ®Google Scholar
• Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995;3(1):87-98
   PubMed Web of Science ®Google Scholar
• Howland KC, Ausubel LJ, London CA, Abbas AK. The roles of CD28 and CD40 ligand in T cell activation and tolerance. J Immunol 2000;164(9):4465-70
   PubMed Web of Science ®Google Scholar
• Khoury SJ, Sayegh MH. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity 2004;20(5):529-38
   PubMed Web of Science ®Google Scholar
• Ito T, Ueno T, Clarkson MR, et al. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J Immunol 2005;174(11):6648-56
   PubMed Web of Science ®Google Scholar
• Harada H, Salama AD, Sho M, et al. The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J Clin Invest 2003;112(2):234-43
   PubMed Web of Science ®Google Scholar
• Demirci G, Amanullah F, Kewalaramani R, et al. Critical role of OX40 in CD28 and CD154-independent rejection. J Immunol 2004;172(3):1691-8
   PubMed Web of Science ®Google Scholar
• Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006;203(4):883-95
   PubMed Web of Science ®Google Scholar
• Li XC, Rothstein DM, Sayegh MH. Costimulatory pathways in transplantation: challenges and new developments. Immunol Rev 2009;229(1):271-93
   PubMedGoogle Scholar
• Riella LV, Watanabe T, Sage PT, et al. Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts. Am J Transplant 2011;11(4):832-40
   PubMed Web of Science ®Google Scholar
• Sandner SE, Clarkson MR, Salama AD, et al. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol 2005;174(6):3408-15
   PubMed Web of Science ®Google Scholar
• Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 2002;13(2):559-75
   PubMed Web of Science ®Google Scholar
• Yang J, Riella LV, Chock S, et al. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol 2011;187(3):1113-19
   PubMed Web of Science ®Google Scholar
• Zheng XX, Markees TG, Hancock WW, et al. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. J Immunol 1999;162(8):4983-90
   PubMed Web of Science ®Google Scholar
• Tanaka K, Albin MJ, Yuan X, et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol 2007;179(8):5204-10
   PubMed Web of Science ®Google Scholar
• Riella LV, Paterson AM, Sharpe AH, Chandraker A. Role of the PD-1 pathway in the immune response. Am J Transplant 2012;12(10):2575-87
   PubMed Web of Science ®Google Scholar
• Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002;3(11):1097-101
   PubMed Web of Science ®Google Scholar
• Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011;332(6029):600-3
   PubMed Web of Science ®Google Scholar
• Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a Phase I trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006;355(10):1018-28
   PubMed Web of Science ®Google Scholar
• Hausen B, Klupp J, Christians U, et al. Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys. Transplantation 2001;72(6):1128-37
   PubMed Web of Science ®Google Scholar
• Kirk AD, Tadaki DK, Celniker A, et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 2001;72(3):377-84
   PubMed Web of Science ®Google Scholar
• Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174(3):561-9
   PubMed Web of Science ®Google Scholar
• Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992;89(22):11102-5
   PubMed Web of Science ®Google Scholar
• Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992;257(5071):789-92
   PubMed Web of Science ®Google Scholar
• Levisetti MG, Padrid PA, Szot GL, et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997;159(11):5187-91
   PubMed Web of Science ®Google Scholar
• Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997;94(16):8789-94
   PubMed Web of Science ®Google Scholar
• Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005;5(3):443-53
   PubMed Web of Science ®Google Scholar
• Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005;353(8):770-81
   PubMed Web of Science ®Google Scholar
• Vincenti F, Charpentier B, Vanrenterghem Y, et al. A Phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010;10(3):535-46
   PubMed Web of Science ®Google Scholar
• Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012;12(3):630-9
   PubMed Web of Science ®Google Scholar
• Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012;12(1):210-17
   PubMed Web of Science ®Google Scholar
• Klintmalm GB FS, Lake JR, et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II study (abstract no. 355). Am J Transplant 2011;11(Suppl 2):137
   Google Scholar
• Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003;111(12):1887-95
   PubMed Web of Science ®Google Scholar
• Braciale TJ, Andrew ME, Braciale VL. Simultaneous expression of H-2-restricted and alloreactive recognition by a cloned line of influenza virus-specific cytotoxic T lymphocytes. J Exp Med 1981;153(5):1371-6
   PubMed Web of Science ®Google Scholar
• Amir AL, D'Orsogna LJ, Roelen DL, et al. Allo-HLA reactivity of virus-specific memory T cells is common. Blood 2010;115(15):3146-57
   PubMed Web of Science ®Google Scholar
• Wu Z, Bensinger SJ, Zhang J, et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004;10(1):87-92
   PubMed Web of Science ®Google Scholar
• Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005;5(3):465-74
   PubMed Web of Science ®Google Scholar
• Jameson SC, Masopust D. Diversity in T cell memory: an embarrassment of riches. Immunity 2009;31(6):859-71
   PubMed Web of Science ®Google Scholar
• Valujskikh A, Pantenburg B, Heeger PS. Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am J Transplant 2002;2(6):501-9
   PubMed Web of Science ®Google Scholar
• Kitchens WH, Haridas D, Wagener ME, et al. Integrin antagonists prevent costimulatory blockade-resistant transplant rejection by CD8(+) memory T cells. Am J Transplant 2012;12(1):69-80
   PubMed Web of Science ®Google Scholar
• Weaver TA, Charafeddine AH, Agarwal A, et al. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med 2009;15(7):746-9
   PubMed Web of Science ®Google Scholar
• Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003;3(3):199-210
   PubMed Web of Science ®Google Scholar
• Nadig SN, Wieckiewicz J, Wu DC, et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010;16(7):809-13
   PubMed Web of Science ®Google Scholar
• Joffre O, Santolaria T, Calise D, et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 2008;14(1):88-92
   PubMed Web of Science ®Google Scholar
• Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000;12(4):431-40
   PubMed Web of Science ®Google Scholar
• Tang Q, Henriksen KJ, Boden EK, et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 2003;171(7):3348-52
   PubMed Web of Science ®Google Scholar
• Riella LV, Liu T, Yang J, et al. Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model. Am J Transplant 2012;12(4):846-55
   PubMed Web of Science ®Google Scholar
• Lechler RI, Garden OA, Turka LA. The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol 2003;3(2):147-58
   PubMed Web of Science ®Google Scholar
• Semple K, Nguyen A, Yu Y, et al. Strong CD28 costimulation suppresses induction of regulatory T cells from naive precursors through Lck signaling. Blood 2011;117(11):3096-103
   PubMed Web of Science ®Google Scholar
• Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111-35
   PubMed Web of Science ®Google Scholar
• Kawai T, Andrews D, Colvin RB, et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000;6(2):114
   Web of Science ®Google Scholar
• Xu H, Zhang X, Mannon RB, Kirk AD. Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154. J Clin Invest 2006;116(3):769-74
   PubMed Web of Science ®Google Scholar
• Adams AB, Shirasugi N, Jones TR, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 2005;174(1):542-50
   PubMed Web of Science ®Google Scholar
• Aoyagi T, Yamashita K, Suzuki T, et al. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy. Am J Transplant 2009;9(8):1732-41
   PubMed Web of Science ®Google Scholar
• Haanstra KG, Ringers J, Sick EA, et al. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation 2003;75(5):637-43
   PubMed Web of Science ®Google Scholar
• Haanstra KG, Sick EA, Ringers J, et al. Costimulation blockade followed by a 12-week period of cyclosporine A facilitates prolonged drug-free survival of rhesus monkey kidney allografts. Transplantation 2005;79(11):1623-6
   PubMed Web of Science ®Google Scholar
• Imai A, Suzuki T, Sugitani A, et al. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation 2007;84(8):1020-8
   PubMed Web of Science ®Google Scholar
• Pearson TC, Trambley J, Odom K, et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002;74(7):933-40
   PubMed Web of Science ®Google Scholar
• Badell IR, Russell MC, Cardona K, et al. CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8. Am J Transplant 2012;12(7):1918-23
   PubMed Web of Science ®Google Scholar
• Vu MD, Clarkson MR, Yagita H, et al. Critical, but conditional, role of OX40 in memory T cell-mediated rejection. J Immunol 2006;176(3):1394-401
   PubMed Web of Science ®Google Scholar
• Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008;224:166-82
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, Hwang KW, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003;4(12):1206-12
   PubMed Web of Science ®Google Scholar
• Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995;270(5238):985-8
   PubMed Web of Science ®Google Scholar
• Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008;322(5899):271-5
   PubMed Web of Science ®Google Scholar
• Butte M, Keir M, Phamduy T, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007;27(1):111-33
   PubMed Web of Science ®Google Scholar
• Park JJ, Omiya R, Matsumura Y, et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 2010;116(8):1291-8
   PubMed Web of Science ®Google Scholar
• Yi T, Li X, Yao S, et al. Host APCs augment in vivo expansion of donor natural regulatory T cells via B7H1/B7.1 in allogeneic recipients. J Immunol 2011;186(5):2739-49
   PubMed Web of Science ®Google Scholar
• Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17 deficient mice. J Immunol 2003;171(11):6173-7
   PubMed Web of Science ®Google Scholar
• Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008;172(1):146-55
   PubMed Web of Science ®Google Scholar
• Burrell BE, Bishop DK. Th17 cells and transplant acceptance. Transplantation 2010;90(9):945-8
   PubMed Web of Science ®Google Scholar
• Antonysamy MA, Fanslow WC, Fu F, et al. Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol 1999;162(1):577-84
   PubMed Web of Science ®Google Scholar
• Tang JL, Subbotin VM, Antonysamy MA, et al. Interleukin-17 antagonism inhibits acute but not chronic vascular rejection. Transplantation 2001;72(2):348-50
   PubMed Web of Science ®Google Scholar
• Yuan X, Ansari MJ, D'Addio F, et al. Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Proc Natl Acad Sci USA 2009;106(26):10734-9
   PubMed Web of Science ®Google Scholar
• Burrell BE, Csencsits K, Lu G, et al. CD8+ Th17 mediate costimulation blockade-resistant allograft rejection in T-bet-deficient mice. J Immunol 2008;181(6):3906-14
   PubMed Web of Science ®Google Scholar
• Bouguermouh S, Fortin G, Baba N, et al. CD28 co-stimulation down regulates Th17 development. PLoS One 2009;4(3):e5087
   PubMed Web of Science ®Google Scholar
• Ying H, Yang L, Qiao G, et al. Cutting edge: CTLA-4–B7 interaction suppresses Th17 cell differentiation. J Immunol 2010;185(3):1375-8
   PubMed Web of Science ®Google Scholar
• Grinyo J, Charpentier B, Pestana JM, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010;90(12):1521-7
   PubMed Web of Science ®Google Scholar
• Dolfi DV, Duttagupta PA, Boesteanu AC, et al. Dendritic cells and CD28 costimulation are required to sustain virus-specific CD8+ T cell responses during the effector phase in vivo. J Immunol 2011;186(8):4599-608
   PubMed Web of Science ®Google Scholar
• Durrbach A, Medina-Pestana JO, Rostaing L, et al. Improving or maintaining renal function with belatacept: 5-year benefit long-term extension results [abstract BO 199]. Oral presentation at the European Society of Organ Transplantation; 2013
   Google Scholar
• El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009;9(3):527-35
   PubMed Web of Science ®Google Scholar
• Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012;12(5):1157-67
   PubMed Web of Science ®Google Scholar
• Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol 2011;6(2):430-9
   PubMed Web of Science ®Google Scholar
• Lo DJ, Anderson DJ, Weaver TA, et al. Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. Am J Transplant 2013;13(2):320-8
   PubMed Web of Science ®Google Scholar
• Ferguson R, Grinyo J, Vincenti F, et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011;11(1):66-76
   PubMed Web of Science ®Google Scholar
• Urakami H, Ostanin DV, Hunig T, Grisham MB. Combination of donor-specific blood transfusion with anti-CD28 antibody synergizes to prolong graft survival in rat liver transplantation. Transplant Proc 2006;38(10):3244-6
   PubMed Web of Science ®Google Scholar
• Azuma H, Isaka Y, Li X, et al. Superagonistic CD28 antibody induces donor-specific tolerance in rat renal allografts. Am J Transplant 2008;8(10):2004-14
   PubMed Web of Science ®Google Scholar
• Vanhove B, Laflamme G, Coulon F, et al. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody. Blood 2003;102(2):564-70
   PubMed Web of Science ®Google Scholar
• Poirier N, Azimzadeh AM, Zhang T, et al. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med 2010;2(17):17ra0
   Web of Science ®Google Scholar
• Zhang T, Fresnay S, Welty E, et al. Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transplant 2011;11(8):1599-609
   PubMed Web of Science ®Google Scholar
• Poirier N, Mary C, Dilek N, et al. Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody. Am J Transplant 2012;12(10):2630-40
   PubMed Web of Science ®Google Scholar
• Ashoor I, Najafian N, Korin Y, et al. Standardization and cross validation of alloreactive IFNgamma ELISPOT assays within the clinical trials in organ transplantation consortium. Am J Transplant 2013;13(7):1871-9
   PubMed Web of Science ®Google Scholar
• Hricik DE, Nickerson P, Formica RN, et al. Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant 2013; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011;12(1):56-68
   PubMed Web of Science ®Google Scholar
• Riella L, Bromberg JS. Literature watch: implications for transplantation. Am J Transplant 2013;13(1):3
   PubMedGoogle Scholar
• Lee MJ, Ye AS, Gardino AK, et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012;149(4):780-94
   PubMed Web of Science ®Google Scholar
• Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007;18(4):1046-56
   PubMed Web of Science ®Google Scholar